Swenson, Anna
Paulus, Jessica K.
Jung, Yoojin
Weiss, Stefan
Berman, Brian
Peeva, Elena
Yamaguchi, Yuji
George, Prethibha
Jagun, Oladayo
Funding for this research was provided by:
Pfizer
Article History
Received: 28 August 2023
Accepted: 9 November 2023
First Online: 8 December 2023
Declarations
:
: At the time of the study, Prethibha George was an employee of Pfizer Inc and may hold stock or stock options in Pfizer Inc; Prethibha George has no current affiliation. Elena Peeva, Yuji Yamaguchi, and Oladayo Jagun are employees of and may hold stock or stock options in Pfizer Inc. Anna Swenson, Yoojin Jung, and Stefan Weiss are employees of OM1, Inc. At the time of the study, Jessica Paulus was an employee of OM1 Inc.; Jessica Paulus’ current affiliation is Ontada LLC, Boston, MA, USA. Pfizer Inc engaged and provided funding to OM1 Inc to conduct this study.
: The study was conducted in accordance with legal and regulatory requirements, as well as with scientific purpose, value, and rigor and follows generally accepted research practices described in Good Pharmacoepidemiology Practices issued by the International Society for Pharmacoepidemiology, the International Society for Pharmacoeconomics and Outcomes Research guidance, Pharmaceutical Research and Manufacturers Association guidelines, and applicable regulatory requirements. All database records were deidentified in compliance with the US Health Insurance Portability and Accountability Act (HIPAA); therefore, informed consent from patients was not needed or obtained, and approval from an institutional review board was not required.